Zoetis Inc (ZTS) Receives Average Recommendation of “Buy” from Analysts

Zoetis Inc (NYSE:ZTS) has been given an average rating of “Buy” by the twenty ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and fourteen have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $73.72.

Several brokerages have weighed in on ZTS. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Thursday, October 12th. BidaskClub downgraded Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. BMO Capital Markets raised their price target on Zoetis to $78.00 and gave the stock a “market perform” rating in a report on Tuesday, January 9th. Craig Hallum reissued a “buy” rating and issued a $85.00 price target (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald set a $85.00 price target on Zoetis and gave the stock a “buy” rating in a report on Tuesday, January 2nd.

Shares of Zoetis (NYSE ZTS) traded up $0.29 during midday trading on Friday, reaching $76.62. The company’s stock had a trading volume of 3,476,402 shares, compared to its average volume of 1,950,000. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The firm has a market capitalization of $37,340.00, a P/E ratio of 40.33, a PEG ratio of 1.83 and a beta of 1.06. Zoetis has a fifty-two week low of $52.00 and a fifty-two week high of $77.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the company earned $0.52 earnings per share. analysts expect that Zoetis will post 2.36 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be issued a dividend of $0.126 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.66%. Zoetis’s payout ratio is 26.32%.

Institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its position in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after acquiring an additional 230 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Zoetis during the third quarter valued at approximately $114,000. Harfst & Associates Inc. raised its position in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after acquiring an additional 260 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares in the last quarter. Finally, Shine Investment Advisory Services Inc. raised its position in Zoetis by 86.5% during the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after acquiring an additional 1,040 shares in the last quarter. 93.14% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zoetis Inc (ZTS) Receives Average Recommendation of “Buy” from Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/20/zoetis-inc-zts-receives-average-recommendation-of-buy-from-analysts.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply